Drugs Containing Excipient (Inactive Ingredient) PEG-32 HYDROGENATED PALM GLYCERIDES

« Back to Dashboard

Branded drugs containing PEG-32 HYDROGENATED PALM GLYCERIDES excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sun Pharmaceutical Industries Inc	ABSORICA	isotretinoin	10631-115	PEG-32 HYDROGENATED PALM GLYCERIDES
L'Oreal USA Products Inc	LA ROCHE POSAY LABORATOIRE DERMATOLOGIQUE ANTHELIOS SX DAILY MOISTURIZING SUNSCREEN BROAD SPECTRUM SPF 15	avobenzone, ecamsule and octocrylene	49967-017	PEG-32 HYDROGENATED PALM GLYCERIDES

Generic drugs containing PEG-32 HYDROGENATED PALM GLYCERIDES excipient

Company	Ingredient	NDC	Excipient
Actavis Pharma Inc	isotretinoin	0591-2433	PEG-32 HYDROGENATED PALM GLYCERIDES
Sun Pharmaceutical Industries Inc	isotretinoin	10631-115	PEG-32 HYDROGENATED PALM GLYCERIDES
L'Oreal USA Products Inc	avobenzone, ecamsule and octocrylene	49967-017	PEG-32 HYDROGENATED PALM GLYCERIDES
Zydus Pharmaceuticals USA Inc	isotretinoin	70710-1574	PEG-32 HYDROGENATED PALM GLYCERIDES

PEG-32 Hydrogenated Palm Glycerides Market Dynamics and Financial Trajectory

Last updated: October 4, 2026

PEG-32 hydrogenated palm glycerides is a specialty pharmaceutical excipient used primarily in oral formulations requiring solubilization, wetting, dispersion, modified release, or improved bioavailability. Its commercial outlook is tied to lipid-based drug delivery, poorly water-soluble active pharmaceutical ingredients, generic reformulation, and supplier qualification requirements.

The excipient is not a standalone public financial reporting category. Suppliers generally report it within broader excipient, lipid delivery, solubilizer, surfactant, or pharmaceutical ingredients portfolios. Public sources therefore support a directional market assessment, but not a defensible standalone revenue figure or company-specific market share.

What is PEG-32 hydrogenated palm glycerides?

PEG-32 hydrogenated palm glycerides is a nonionic, polyethylene glycol-based glyceride excipient derived from hydrogenated palm feedstocks. The material combines a hydrophilic PEG component with fatty glyceride chains.

Typical formulation functions include:

Function	Formulation effect
Solubilizer	Improves apparent solubility of poorly water-soluble drugs
Surfactant	Reduces interfacial tension and supports dispersion
Wetting agent	Improves contact between solid drug particles and dissolution media
Lipid vehicle	Supports self-emulsifying and self-microemulsifying systems
Bioavailability enhancer	Can increase drug exposure by improving dissolution or maintaining supersaturation
Processing aid	Supports melt granulation, hot-melt processing, and lipid-based coating systems

The exact composition, hydrophilic-lipophilic balance, melting range, free PEG content, glyceride distribution, and residual impurities depend on the supplier specification. Pharmaceutical developers should not treat all PEG glyceride materials as interchangeable.

Commercially related excipients include PEG esters, macrogolglycerol hydroxystearate, PEG stearates, polyglyceryl esters, glyceryl palmitostearate, and other lipid-based solubilizers. These materials can compete in a formulation even when their chemical identities differ.

How large is the PEG-32 hydrogenated palm glycerides market?

No authoritative public source reports a standalone global market size for PEG-32 hydrogenated palm glycerides. The material is usually grouped into broader categories such as pharmaceutical excipients, lipid excipients, solubilizers, surfactants, or drug-delivery ingredients.

Its addressable market is best evaluated through end-use demand rather than a reported ingredient revenue number.

Demand indicator	Directional impact
Increasing use of poorly soluble APIs	Positive
Growth in oral lipid-based delivery	Positive
Generic reformulation and bioequivalence optimization	Positive
Expansion of softgel and lipid-filled hard-capsule products	Positive
Greater scrutiny of residual solvents and impurities	Mixed
Palm-derived raw-material price volatility	Negative
Qualification of alternate suppliers	Positive for qualified producers
Substitution by PEG esters or synthetic surfactants	Negative
Demand for excipient traceability and sustainability	Mixed

The highest-value applications are not necessarily the highest-volume applications. A small quantity used in a difficult-to-formulate drug can have greater commercial value than a larger quantity used in a conventional tablet.

What is driving demand for PEG-32 hydrogenated palm glycerides?

Poorly water-soluble drug development

A large share of new small-molecule drug candidates has limited aqueous solubility. Lipid excipients can improve dissolution, dispersion, and intestinal absorption. This creates demand for excipient systems that can be screened quickly across multiple APIs.

PEG-32 hydrogenated palm glycerides is most commercially relevant when a formulation team needs a multifunctional material rather than a simple filler or binder. It can participate in self-emulsifying drug delivery systems, lipid suspensions, melt-based processing, and solidified lipid formulations.

Generic drug reformulation

Generic manufacturers use lipid excipients to address dissolution, food-effect, and bioequivalence challenges. Reformulation demand can arise when:

• The reference product has a complex dissolution profile.
• The API has low or variable solubility.
• A conventional formulation fails comparative dissolution testing.
• A manufacturer seeks a smaller dosage form.
• The generic product requires improved stability or content uniformity.

The commercial cycle is usually longer than ordinary excipient replacement because the excipient must be qualified, incorporated into process development, and assessed in regulatory submissions.

Oral delivery and lipid-based systems

Lipid-based formulations remain important for APIs in Biopharmaceutics Classification System Class II and some Class IV categories. The material can support:

• Self-emulsifying drug delivery systems.
• Self-microemulsifying drug delivery systems.
• Lipid-filled capsules.
• Amorphous or partially amorphous solid dispersions.
• Melt granulation.
• Drug-loaded lipid microparticles.
• Taste-masked or modified-release oral dosage forms.

Its value depends on the full formulation architecture. A formulation may require a blend with medium-chain triglycerides, long-chain glycerides, ethanol, propylene glycol, polysorbates, or other surfactants.

Which companies supply or compete with PEG-32 hydrogenated palm glycerides?

The competitive landscape is fragmented because suppliers often market branded excipient systems rather than the generic chemical name alone.

Principal competitive groups

Supplier group	Relevant competitive products or technologies
Gattefossé	Gelucire, Labrasol, Transcutol and related lipid excipients
BASF	Kolliphor and related solubilizers, surfactants, and lipid excipients
Croda	Pharmaceutical-grade PEG esters, surfactants, and specialty excipients
Evonik	Drug-delivery excipients, formulation technologies, and specialty lipids
IOI Oleo	Pharmaceutical glycerides and lipid excipients
ABITEC	Capmul and related glyceride-based excipients
Regional excipient producers	PEG esters, glycerides, surfactants, and formulation blends

Brand equivalence cannot be assumed from a similar HLB value or shared functional description. Developers typically compare melting behavior, peroxide value, acid value, hydroxyl value, water content, particle characteristics, dissolution performance, and impurity profile.

Supplier differentiation is based on more than chemistry. Manufacturing consistency, regulatory documentation, global supply, technical support, change-control procedures, and drug-master-file support can determine which material is selected.

What formulations are protected by PEG-32 hydrogenated palm glycerides?

The excipient can be used in several formulation platforms, but its presence does not itself create a proprietary formulation.

Oral solid dosage forms

Potential uses include:

• Direct-compression or wet-granulated tablets.
• Lipid-based granules.
• Melt-granulated tablets.
• Solidified self-emulsifying systems.
• Immediate-release formulations for poorly soluble APIs.
• Modified-release matrices.

The main development risks are content uniformity, interaction with tablet disintegrants, dissolution variability, and physical changes during storage.

Capsules and softgels

The material may be used in liquid or semisolid fills, particularly where the API requires a surfactant or self-emulsifying vehicle. Softgel systems require compatibility testing with gelatin or alternative capsule shells, seal integrity testing, and long-term migration assessment.

Solid dispersions and hot-melt processing

PEG-containing glycerides can support thermally processed systems, but the acceptable process temperature depends on the API, excipient melting range, degradation profile, and equipment. Thermal exposure can affect peroxide formation and API stability.

How strong is the patent estate for PEG-32 hydrogenated palm glycerides?

The ingredient-level patent estate is generally weaker than the formulation-level estate because many glyceride and PEG ester compositions have long histories of pharmaceutical and nonpharmaceutical use.

The commercially important intellectual property is more likely to cover:

• Specific drug-excipient ratios.
• Self-emulsifying formulations.
• Solid lipid dispersions.
• Controlled-release systems.
• Manufacturing processes.
• Particle engineering.
• Combination excipient systems.
• Specific therapeutic uses of a formulated drug.

A patent claim directed to a finished pharmaceutical composition may identify a PEG glyceride as one option among numerous excipients. That does not necessarily give the excipient supplier control over the broader ingredient market.

Patent and regulatory distinctions

Question	Answer
Is PEG-32 hydrogenated palm glycerides an approved drug?	No. It is an excipient used in drug products.
Is it listed in the Orange Book as an active ingredient?	No. The Orange Book lists approved drug products and related patent information, not a standalone excipient market.
Can an excipient be named in a Paragraph IV certification?	Not by itself. Paragraph IV certifications address patents listed for an approved drug product.
Can a formulation using the excipient be patented?	Yes. Composition, process, and method-of-use claims may cover a finished drug product.
Does an excipient supplier automatically control those patents?	No. Patents are owned by the applicant, formulation developer, or other rights holder.
Are biosimilar risks relevant?	Generally no. PEG-32 hydrogenated palm glycerides is primarily relevant to small-molecule and oral formulations, not biosimilar interchangeability.

What is the FDA regulatory status of PEG-32 hydrogenated palm glycerides?

The regulatory status depends on the specific product, route, concentration, grade, and manufacturing controls. The FDA Inactive Ingredient Database is the principal public reference for identifying excipients used in approved drug products and the routes and dosage forms in which they have precedent.[1]

A listing in the Inactive Ingredient Database does not mean that every grade, supplier, concentration, or route is automatically acceptable. Sponsors must establish suitability for the intended product and manufacturing process.

Key regulatory considerations include:

• Compendial identity and quality requirements where applicable.
• Residual solvents and elemental impurities.
• Peroxide and aldehyde formation.
• Microbial quality.
• Residual ethylene oxide or related process impurities where relevant.
• PEG-related impurity control.
• Pesticide and agricultural-residue controls for palm-derived feedstocks.
• Allergen and cross-contamination statements.
• Nitrosamine risk assessment where the formulation and manufacturing process create a relevant pathway.
• Stability of the excipient and finished dosage form.
• Supplier change-control history.

For European applications, excipient suitability is assessed through the finished product dossier and relevant European Pharmacopoeia, ICH, and EMA expectations. The European Commission’s excipient-guideline framework also emphasizes documentation of excipient quality and pharmaceutical function.[2]

How do palm-derived raw materials affect the financial trajectory?

Hydrogenated palm feedstocks create both cost and commercial opportunities.

Cost factors

The largest cost variables are generally:

1. Palm oil and palm-kernel derivatives.
2. Hydrogenation and esterification inputs.
3. PEG raw-material pricing.
4. Energy and utilities.
5. Quality-control testing.
6. Pharmaceutical-grade packaging and logistics.
7. Regulatory documentation and audit support.

The excipient is more exposed to feedstock and processing costs than a simple inorganic filler. However, its selling price reflects functional performance, regulatory qualification, and supply assurance rather than raw-material cost alone.

Sustainability and procurement pressure

Pharmaceutical customers increasingly request:

• Palm sustainability certifications.
• Traceability to plantation or mill level.
• Deforestation-risk assessments.
• RSPO-related documentation where applicable.
• Carbon and water-impact data.
• Conflict-mineral and modern-slavery statements.
• Animal-origin and GMO declarations.

Sustainability requirements can increase supplier costs, but they can also strengthen incumbent suppliers that already have qualified documentation and auditable supply chains.

What is the financial trajectory for the excipient?

The likely trajectory is moderate, formulation-driven growth rather than explosive volume expansion.

Near-term trajectory

Demand should remain supported by:

• Development of poorly soluble oral drugs.
• Generic product optimization.
• Expansion of lipid-based delivery systems.
• Increased use of enabling excipients during preformulation.
• Demand for lower-dose and higher-exposure formulations.

Pricing power is strongest when the excipient is embedded in an approved product or validated manufacturing process. Once qualified, substitution can require formulation redevelopment, stability work, dissolution testing, and regulatory documentation.

Medium-term trajectory

Growth will depend on whether manufacturers can demonstrate a clear performance advantage over competing excipients. Materials with similar functionality face substitution from:

• PEG esters.
• Macrogolglycerol hydroxystearate.
• Polysorbates.
• Sucrose esters.
• Polyglyceryl esters.
• Synthetic amphiphilic polymers.
• Lipid nanoparticle and advanced delivery technologies.

The financial profile is therefore likely to divide into two segments:

Segment	Financial characteristics
Commodity or near-commodity glyceride supply	Volume-sensitive, margin pressure, feedstock exposure
Qualified pharmaceutical-grade excipient systems	Higher margins, longer customer retention, stronger switching costs

Public company filings generally do not isolate revenue from PEG-32 hydrogenated palm glycerides. Revenue exposure must be estimated from broader pharmaceutical-excipient segments, product portfolios, capacity expansion, and customer qualification activity.

What generic launch risks exist?

Generic launch risk is indirect but commercially relevant. The excipient may affect whether a generic formulation achieves bioequivalence and acceptable dissolution.

Key risks include:

• Failure to reproduce the reference product’s solubilization profile.
• Excipient variability across lots.
• Changes in melting behavior.
• Stability failures linked to oxidation.
• Incompatibility with the API or capsule shell.
• Inadequate supplier documentation.
• Delayed alternate-source qualification.
• Regulatory questions about novel use or concentration.
• Manufacturing scale-up failure.

A generic manufacturer that relies on a single qualified source may face supply interruption risk. Dual sourcing is desirable but can be difficult because nominally equivalent materials may produce different dissolution or process results.

What licensing deals and litigation affect the market?

No major public licensing transaction or Orange Book litigation is uniquely associated with PEG-32 hydrogenated palm glycerides as an ingredient category.

Licensing activity is more likely to occur around:

• Drug-delivery platforms.
• Branded formulations.
• CDMO development programs.
• Proprietary self-emulsifying systems.
• Solid-dispersion technologies.
• Finished pharmaceutical products.

Likewise, litigation involving the excipient would generally concern a formulation patent, manufacturing process, or finished drug product rather than ownership of the generic excipient name. Patent-risk analysis therefore requires product-specific review of issued claims, continuations, terminal disclaimers, prosecution history, and jurisdictional status.

How does PEG-32 hydrogenated palm glycerides compare with competing excipients?

Attribute	PEG-32 hydrogenated palm glycerides	PEG esters	Macrogolglycerol hydroxystearate	Polysorbates
Primary role	Lipid-based solubilization and dispersion	Solubilization and wetting	Strong solubilization and emulsification	Surfactant and emulsifier
Feedstock profile	Hydrogenated palm glycerides and PEG	Fatty acids and PEG	Hydrogenated castor-oil derivatives and PEG	Sorbitan esters and PEG
Solid dosage suitability	Generally favorable for lipid systems	Depends on grade	More often liquid or semisolid	Often liquid
Oxidation concern	Requires control	Grade-dependent	Requires control	Known oxidation sensitivity
Main advantage	Multifunctional lipid behavior	Broad formulation flexibility	Strong emulsification	Established regulatory use
Main limitation	Composition and source variability	Potential substitution and impurity concerns	Viscosity and oxidative stability	Peroxide and degradation concerns

The practical winner is determined by API chemistry, process design, dosage form, stability profile, and regulatory precedent.

Key Takeaways

• PEG-32 hydrogenated palm glycerides is a specialty pharmaceutical excipient for solubilization, wetting, dispersion, and lipid-based oral delivery.
• No reliable public source reports a standalone market size or revenue series for the ingredient.
• Demand is linked to poorly soluble APIs, generic reformulation, self-emulsifying systems, and lipid-based dosage forms.
• The highest commercial value is in qualified pharmaceutical-grade supply, not commodity glyceride volume.
• Palm-derived feedstocks create exposure to raw-material prices, sustainability requirements, and traceability costs.
• Orange Book listings, Paragraph IV certifications, biosimilar competition, and drug-product litigation generally do not apply to the excipient in isolation.
• Formulation and manufacturing patents may create product-specific barriers, but they do not establish broad ownership of the ingredient.
• Supplier qualification, batch consistency, impurity control, and regulatory documentation are the main competitive barriers.
• Financial growth is likely to be moderate and formulation-led, with stronger margins for validated excipient systems than for undifferentiated material.

FAQs

Is PEG-32 hydrogenated palm glycerides the same as Gelucire 50/13?

Not necessarily. Commercial products can have related PEG glyceride chemistry but different composition, melting behavior, PEG content, and glyceride distribution. Equivalence requires comparison of supplier specifications and formulation performance.

Is PEG-32 hydrogenated palm glycerides suitable for injectable drugs?

The material is primarily associated with oral and pharmaceutical formulation applications. Injectable use requires route-specific toxicology, purity, sterility, endotoxin, and regulatory support. Oral precedent does not establish injectable suitability.

Does PEG-32 hydrogenated palm glycerides improve bioavailability?

It can improve bioavailability when poor dissolution or solubilization limits absorption. The effect depends on the API, dose, formulation ratio, digestion behavior, supersaturation control, and food effect.

Can pharmaceutical manufacturers switch suppliers without new regulatory work?

Usually not automatically. A supplier change can require comparability testing, stability studies, dissolution evaluation, process assessment, and regulatory documentation. The required work depends on the product and jurisdiction.

Is PEG-32 hydrogenated palm glycerides vulnerable to replacement by synthetic surfactants?

Yes, in some formulations. Replacement is most likely where the competing surfactant provides equivalent dissolution, stability, safety, processability, and regulatory support at lower total cost.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

2. European Medicines Agency. (2016). Guideline on the chemistry of active substances. https://www.ema.europa.eu/

3. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary, USP 47-NF 42. U.S. Pharmacopeial Convention.

4. Gattefossé. (n.d.). Pharmaceutical excipients and drug delivery solutions. https://www.gattefosse.com/

5. BASF. (n.d.). Pharma solutions: Excipients and drug delivery. https://pharma.basf.com/

6. International Council for Harmonisation. (2023). ICH Q3C(R8): Impurities: Guideline for residual solvents. https://www.ich.org/

7. International Council for Harmonisation. (2023). ICH Q3D(R2): Guideline for elemental impurities. https://www.ich.org/